Disclosed is a non-aqueous electrolytic solution for an energy storage device, including a non-aqueous solvent, an electrolyte salt, a first additive consisting of a sulfolane compound represented by the following formula (1), and a second additive which is at least one selected from the group consisting of a cyclic sulfuric ester compound represented by the following formula (2a) and a dinitrile compound represented by the following formula (2b):

##STR00001##

Disclosed is a non-aqueous electrolytic solution for an energy storage device, including a non-aqueous solvent, an electrolyte salt, a first additive consisting of a sulfolane compound represented by the following formula (1), and a second additive which is at least one selected from the group consisting of a cyclic sulfuric ester compound represented by the following formula (2a) and a dinitrile compound represented by the following formula (2b):

##STR00001##

Provided herein are Sulfamate compounds for use in modulating an activity of peptidyl-prolyl isomerase NIMA-interacting-1 (Pin1).

Provided herein are Sulfamate compounds for use in modulating an activity of peptidyl-prolyl isomerase NIMA-interacting-1 (Pin1).

Described herein are novel - and -propargyl carboxylic acids and esters. The novel compositions are antagonists of CSE and may be used to modulate of the activity of the carotid body, therefore providing therapeutic benefits for sleep-related breathing disorders and related conditions.

The present invention is directed to heterocycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and/or GPR40 receptors. More particularly, the compounds of the present invention are agonists of GPR120 and/or GPR40, useful in the treatment of, for example, obesity, Type II Diabetes Mellitus, dyslipidemia, etc.

Inhibitors of HBV replication of Formula (I)

##STR00001##

including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R.sub.1, R.sub.2 and R.sub.4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

Inhibitors of HBV replication of Formula (I)

##STR00001##

including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R.sub.1, R.sub.2 and R.sub.4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

A polymer solid electrolyte having high ion conductivity and interfacial stability is provided. An additive including an organic compound having a highest occupied molecular orbital (HOMO) energy of 8.5 eV or higher is used, which facilitates film formation in a positive electrode due to low oxidation potential. The resulting polymer solid electrolytes have enhanced film formation on the surface of a positive electrode surface and enhanced interfacial stability, while maintaining battery performance. Lithium secondary battery having enhanced performance are also described.

A polymer solid electrolyte having high ion conductivity and interfacial stability is provided. An additive including an organic compound having a highest occupied molecular orbital (HOMO) energy of 8.5 eV or higher is used, which facilitates film formation in a positive electrode due to low oxidation potential. The resulting polymer solid electrolytes have enhanced film formation on the surface of a positive electrode surface and enhanced interfacial stability, while maintaining battery performance. Lithium secondary battery having enhanced performance are also described.